
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is facing initial market challenges in terms of operating expenses and decline in US segment earnings, yet with a potential partnership with Novo Nordisk, it may diversify its targeted market for weight loss prescription drugs as an opportunity for future growth. However, with rising regulatory scrutiny and competition, Hims & Hers must strategically position itself and leverage its brand and offerings to remain a competitive player.
Bears say
Hims & Hers Health is facing multiple challenges that could negatively impact its long-term profitability and growth potential. These include potential regulatory challenges in the highly scrutinized GLP-1 market, potential erosion of customer lifetime value due to rising marketing costs, and the need to constantly optimize its business model to maintain unit economics. However, the company's renewed partnership with Novo Nordisk and strong early demand for its weight loss products provide a glimmer of hope for future growth. It remains to be seen if the company's investments in new specialties, international expansion, personalization, and strategic relationships will pay off and achieve its ambitious 2030 financial targets.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares